Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC) - Net Assets
Based on the latest financial reports, Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC) has net assets worth $196.19 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($204.83 Million) and total liabilities ($8.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Oaktree Acquisition Corp. III Life Scien total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $196.19 Million |
| % of Total Assets | 95.78% |
| Annual Growth Rate | 3.89% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share - Net Assets Trend (2024–2025)
This chart illustrates how Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's net assets have evolved over time, based on quarterly financial data. Check Oaktree Acquisition Corp. III Life Scien tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (2024–2025)
The table below shows the annual net assets of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share from 2024 to 2025. For live valuation and market cap data, see market value of Oaktree Acquisition Corp. III Life Scien.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $194.79 Million | +3.89% |
| 2024-12-31 | $187.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69568600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $201.56 Million | 103.48% |
| Total Equity | $194.79 Million | 100.00% |
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share Competitors by Market Cap
The table below lists competitors of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AME Elite Consortium Bhd
KLSE:5293
|
$212.48 Million |
|
Strike Energy Limited
F:RJN
|
$212.51 Million |
|
Melon SA
SN:MELON
|
$212.52 Million |
|
Iberpapel Gestion SA
MC:IBG
|
$212.58 Million |
|
ThinTech Materials Technology Co Ltd
TWO:3663
|
$212.27 Million |
|
Favite Inc
TW:3535
|
$212.20 Million |
|
XINTE ENERGY CO. CL.H YC1
F:9M7
|
$211.98 Million |
|
SBC Exports Limited
NSE:SBC
|
$211.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 187,504,551 to 194,793,375, a change of 7,288,824 (3.9%).
- Net income of 7,288,824 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.29 Million | +3.74% |
| Total Change | $- | 3.89% |
Book Value vs Market Value Analysis
This analysis compares Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.41x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $7.63 | $10.74 | x |
| 2025-12-31 | $10.15 | $10.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (3.74%) is above the historical average (1.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 1.04x | $-18.75 Million |
| 2025 | 3.74% | 0.00% | 0.00x | 1.04x | $-12.19 Million |
Industry Comparison
This section compares Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $138,186,666
- Average return on equity (ROE) among peers: 6.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC) | $196.19 Million | 0.00% | 0.04x | $212.47 Million |
| Artius II Acquisition Inc. (AACB) | $-60.27K | 0.00% | 0.00x | $234.17 Million |
| Artius II Acquisition Inc. Units (AACBU) | $214.29 Million | 0.06% | 0.07x | $268.87 Million |
| Ares Acquisition Corporation II (AACT) | $952.33 Million | 0.00% | 0.06x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $-435.70 Million | 0.00% | 0.00x | $453.07K |
| Altenergy Acquisition Corp (AEAE) | $4.84 Million | 51.14% | 2.71x | $72.22 Million |
| Activate Energy Acquisition Corp. Class A Ordinary Share (AEAQ) | $223.53 Million | 0.00% | 0.04x | $237.40 Million |
| American Exceptionalism Acquisition Corp. A (AEXA) | $328.45 Million | 0.00% | 0.06x | $401.88 Million |
| Aimei Health Technology Co., Ltd Ordinary Share (AFJK) | $8.04 Million | 13.18% | 0.51x | $38.63 Million |
| Aifeex Nexus Acquisition Corporation (AIFE) | $86.16 Million | -0.10% | 0.01x | $91.13 Million |
| AI TRANSPORTATION ACQUISITION CORP Ordinary shares (AITR) | $-4.24K | 0.00% | 0.00x | $86.22 Million |
About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in … Read more